D. E. Shaw & Co. Inc. Acquires 60,732 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

D. E. Shaw & Co. Inc. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 83.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,772 shares of the company’s stock after buying an additional 60,732 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Dyne Therapeutics were worth $3,152,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. KBC Group NV increased its position in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $257,000. Magnetar Financial LLC bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $263,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock valued at $279,000 after purchasing an additional 1,249 shares during the period. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $11.83 on Monday. The stock’s fifty day moving average is $10.36 and its 200-day moving average is $17.35. The stock has a market capitalization of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 6,237 shares of company stock worth $77,760. Insiders own 14.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Piper Sandler lowered their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective on the stock. HC Wainwright lowered their price objective on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. lowered their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.